Status:
COMPLETED
Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Hypertension, Pulmonary
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study sought to determine whether terbogrel was an effective treatment for primary pulmonary hypertension (PPH) by comparing its efficacy and safety to that of placebo.
Eligibility Criteria
Inclusion
- Primary pulmonary hypertension and New York Health Association (NYHA) chronic heart failure (CHF) functional class II-III
- Ability to walk \>= 50 meters on the 6 minute walk test
- Resting mean pulmonary artery pressure \> 25 mmHg
- Mean right atrial pressure \<= 20 mmHg
- Pulmonary capillary wedge pressure \<= 15 mmHg
- Cardiac index \> 2.5 L/min2
- SvO2 sat. \> 63%
- Male of female at least 18 years old
- Signed written informed consent
Exclusion
- Secondary pulmonary hypertension due to lung or systemic diseases
- Pregnant of nursing women, or women of childbearing potential who are not using adequate methods of birth control
- Concurrent systematic use of aspirin, aspirin like drugs, or non-steroidal anti-inflammatory drugs (NSAIDs)
- Surgery of bleeding from gastrointestinal, genitourinary tract, cerebrum or retina within past 6 weeks
- History of bleeding diathesis or a platelet count less than 70,000/mm3
- Exercise limited by factors other than fatigue or exertional dyspnea, such as arthritis, claudication, angina, chronic obstructive pulmonary disease, or bronchial asthma
- Myocardial infarction, stroke, or transient ischemic attack within the preceding six months
- Systolic blood pressure \< 90 mmHg or \> 180 mmHg, or diastolic blood pressure \> 110 mmHg
- Known drug or alcohol dependency within one year of entry into the study
- Known hypersensitivity to any component of the study formulation, epoprostenol, nitric oxide, or adenosine
- Psychiatric or other illness or condition which, in the opinion of the principal investigator, may interfere with study participation, compliance, or other elements of the protocol
- Participation in an evaluation of an investigational drug within the past 30 days
- Portal hypertension or cirrhosis of the liver
- Congenital heart disease e.g., atrial septal defect; patent foramen ovale does not exclude patient from the study
- Appetite suppressants such as fenfluramine, dexfenfluramine, and inhibitors of serotonin uptake known to be associated with primary pulmonary hypertension, received within 3 months of entry into the study
- HIV positive
- Vasodilators. Patients will not receive Ca-channel blockers during the study unless the medication was started prior to the study and the patient has been on a stable dose for at least one month prior to entry
Key Trial Info
Start Date :
May 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT02223481
Start Date
May 1 1998
Last Update
August 22 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.